401 related articles for article (PubMed ID: 10589763)
21. Mullerian inhibiting substance binding and uptake.
Catlin EA; Ezzell RM; Donahoe PK; Manganaro TF; Ebb RG; MacLaughlin DT
Dev Dyn; 1992 Apr; 193(4):295-9. PubMed ID: 1511169
[TBL] [Abstract][Full Text] [Related]
22. Müllerian-inhibiting substance type II receptor expression and function in purified rat Leydig cells.
Lee MM; Seah CC; Masiakos PT; Sottas CM; Preffer FI; Donahoe PK; Maclaughlin DT; Hardy MP
Endocrinology; 1999 Jun; 140(6):2819-27. PubMed ID: 10342873
[TBL] [Abstract][Full Text] [Related]
23. Enhanced purification and production of Müllerian inhibiting substance for therapeutic applications.
Donahoe PK; Clarke T; Teixeira J; Maheswaran S; MacLaughlin DT
Mol Cell Endocrinol; 2003 Dec; 211(1-2):37-42. PubMed ID: 14656474
[TBL] [Abstract][Full Text] [Related]
24. Transforming growth factors type beta 1 and beta 2 are equipotent growth inhibitors of human breast cancer cell lines.
Zugmaier G; Ennis BW; Deschauer B; Katz D; Knabbe C; Wilding G; Daly P; Lippman ME; Dickson RB
J Cell Physiol; 1989 Nov; 141(2):353-61. PubMed ID: 2808542
[TBL] [Abstract][Full Text] [Related]
25. Genetic studies of MIS signalling in sexual development.
Jamin SP; Arango NA; Mishina Y; Behringer RR
Novartis Found Symp; 2002; 244():157-64; discussion 164-8, 203-6, 253-7. PubMed ID: 11990789
[TBL] [Abstract][Full Text] [Related]
26. Mullerian duct regression and antiproliferative bioactivities of mullerian inhibiting substance reside in its carboxy-terminal domain.
MacLaughlin DT; Hudson PL; Graciano AL; Kenneally MK; Ragin RC; Manganaro TF; Donahoe PK
Endocrinology; 1992 Jul; 131(1):291-6. PubMed ID: 1612008
[TBL] [Abstract][Full Text] [Related]
27. AAV9 delivering a modified human Mullerian inhibiting substance as a gene therapy in patient-derived xenografts of ovarian cancer.
Pépin D; Sosulski A; Zhang L; Wang D; Vathipadiekal V; Hendren K; Coletti CM; Yu A; Castro CM; Birrer MJ; Gao G; Donahoe PK
Proc Natl Acad Sci U S A; 2015 Aug; 112(32):E4418-27. PubMed ID: 26216943
[TBL] [Abstract][Full Text] [Related]
28. Müllerian inhibiting substance inhibits branching morphogenesis and induces apoptosis in fetal rat lung.
Catlin EA; Tonnu VC; Ebb RG; Pacheco BA; Manganaro TF; Ezzell RM; Donahoe PK; Teixeira J
Endocrinology; 1997 Feb; 138(2):790-6. PubMed ID: 9003016
[TBL] [Abstract][Full Text] [Related]
29. Differential expression of anti-Müllerian hormone (amh) and anti-Müllerian hormone receptor type II (amhrII) in the teleost medaka.
Klüver N; Pfennig F; Pala I; Storch K; Schlieder M; Froschauer A; Gutzeit HO; Schartl M
Dev Dyn; 2007 Jan; 236(1):271-81. PubMed ID: 17075875
[TBL] [Abstract][Full Text] [Related]
30. Down-regulation of transforming growth factor beta receptors by androgen in ovarian cancer cells.
Evangelou A; Jindal SK; Brown TJ; Letarte M
Cancer Res; 2000 Feb; 60(4):929-35. PubMed ID: 10706107
[TBL] [Abstract][Full Text] [Related]
31. Müllerian inhibiting substance as a model for the transforming growth factor-beta family: development of new treatment strategies.
Shah PC; Simpson BB; Donahoe PK
Semin Pediatr Surg; 1996 Aug; 5(3):182-90. PubMed ID: 8858765
[TBL] [Abstract][Full Text] [Related]
32. Sexually dimorphic expression of a teleost homologue of Müllerian inhibiting substance during gonadal sex differentiation in Japanese flounder, Paralichthys olivaceus.
Yoshinaga N; Shiraishi E; Yamamoto T; Iguchi T; Abe S; Kitano T
Biochem Biophys Res Commun; 2004 Sep; 322(2):508-13. PubMed ID: 15325259
[TBL] [Abstract][Full Text] [Related]
33. Müllerian inhibiting substance blocks epidermal growth factor receptor phosphorylation in fetal rat lung membranes.
Catlin EA; Uitvlugt ND; Donahoe PK; Powell DM; Hayashi M; MacLaughlin DT
Metabolism; 1991 Nov; 40(11):1178-84. PubMed ID: 1943746
[TBL] [Abstract][Full Text] [Related]
34. The serine/threonine transmembrane receptor ALK2 mediates Müllerian inhibiting substance signaling.
Visser JA; Olaso R; Verhoef-Post M; Kramer P; Themmen AP; Ingraham HA
Mol Endocrinol; 2001 Jun; 15(6):936-45. PubMed ID: 11376112
[TBL] [Abstract][Full Text] [Related]
35. Antibody against avian müllerian inhibiting substance (MIS) recognizes MIS on rat müllerian duct and human tumor cells.
Wang JJ; Teng CS
Proc Natl Sci Counc Repub China B; 1989 Oct; 13(4):267-75. PubMed ID: 2484046
[TBL] [Abstract][Full Text] [Related]
36. Roles of estrogen receptor alpha (ER alpha) in the regulation of the human Müllerian inhibitory substance (MIS) promoter.
Chen G; Shinka T; Kinoshita K; Yan HT; Iwamoto T; Nakahori Y
J Med Invest; 2003 Aug; 50(3-4):192-8. PubMed ID: 13678390
[TBL] [Abstract][Full Text] [Related]
37. Mullerian Inhibiting Substance inhibits cervical cancer cell growth via a pathway involving p130 and p107.
Barbie TU; Barbie DA; MacLaughlin DT; Maheswaran S; Donahoe PK
Proc Natl Acad Sci U S A; 2003 Dec; 100(26):15601-6. PubMed ID: 14671316
[TBL] [Abstract][Full Text] [Related]
38. Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer.
Connolly DC; Bao R; Nikitin AY; Stephens KC; Poole TW; Hua X; Harris SS; Vanderhyden BC; Hamilton TC
Cancer Res; 2003 Mar; 63(6):1389-97. PubMed ID: 12649204
[TBL] [Abstract][Full Text] [Related]
39. The inhibitory effects of müllerian-inhibiting substance on epidermal growth factor induced proliferation and progesterone production of human granulosa-luteal cells.
Kim JH; Seibel MM; MacLaughlin DT; Donahoe PK; Ransil BJ; Hametz PA; Richards CJ
J Clin Endocrinol Metab; 1992 Sep; 75(3):911-7. PubMed ID: 1517385
[TBL] [Abstract][Full Text] [Related]
40. Natural mutations of the anti-Mullerian hormone type II receptor found in persistent Mullerian duct syndrome affect ligand binding, signal transduction and cellular transport.
Belville C; Maréchal JD; Pennetier S; Carmillo P; Masgrau L; Messika-Zeitoun L; Galey J; Machado G; Treton D; Gonzalès J; Picard JY; Josso N; Cate RL; di Clemente N
Hum Mol Genet; 2009 Aug; 18(16):3002-13. PubMed ID: 19457927
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
